Search

Your search keyword '"Ciceri F"' showing total 1,833 results

Search Constraints

Start Over You searched for: Author "Ciceri F" Remove constraint Author: "Ciceri F"
1,833 results on '"Ciceri F"'

Search Results

1. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study

2. Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy

3. The Golden Meteorite Fall: Fireball Trajectory, Orbit and Meteorite Characterization

6. Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study

7. One-year survival and Quality of Life of first wave COVID-19 invasively ventilated patients in Lombardy, Italy

8. OP0073 UNRAVELING PATHOPHYSIOLOGY AND HEMATOPOIESIS OF VEXAS SYNDROME BY MULTI-OMICS ANALYSIS AND TARGETED GENE EDITING

9. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

11. Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors.

12. Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome

13. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

14. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

17. Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria)

18. miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease

19. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

21. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1

22. Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study

23. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial

24. Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse

25. Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study

27. POS1432 CAR-TREGS FOR SYSTEMIC LUPUS ERYTHEMATOSUS

28. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): A CARTOGRAPHY OF UBA1 GENE TESTING, EPIDEMIOLOGY AND CLINICAL-GENOMIC CHARACTERISTICS: THE VEXAS/MDS ITALIAN EXPERIENCE

29. P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL

30. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey.

31. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy.

32. Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.

33. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

34. Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study

35. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

36. Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study

37. Mesoangioblasts at 20: From the embryonic aorta to the patient bed

38. The Golden meteorite fall: Fireball trajectory, orbit, and meteorite characterization

39. GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT

40. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT

41. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 y with Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study

43. Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: role of depression and impact on quality of life

45. Properties of Rubble-Pile Asteroid (101955) Bennu from OSIRIS-REx Imaging and Thermal Analysis

49. P013 - Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): A CARTOGRAPHY OF UBA1 GENE TESTING, EPIDEMIOLOGY AND CLINICAL-GENOMIC CHARACTERISTICS: THE VEXAS/MDS ITALIAN EXPERIENCE

Catalog

Books, media, physical & digital resources